---
title: "Medicinal Plants and Diabetic Nephropathy: Phytochemicals, Mechanisms, and Therapeutic Potential"
id: "frontiers-in-immunology-2-medicinal-plants-in-diabetic-nephropathy-bioactive-compounds-mechanisms-and"
canonical_url: "https://medichelpline.com/clinical-feed/frontiers-in-immunology-2-medicinal-plants-in-diabetic-nephropathy-bioactive-compounds-mechanisms-and"
content_type: "clinical_feed_article"
specialty: "Nephrology"
source_name: "Frontiers in Immunology"
source_url: "https://www.frontiersin.org/articles/10.3389/fimmu.2026.1964602"
published_at: "2026-11-12T00:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Medicinal Plants and Diabetic Nephropathy: Phytochemicals, Mechanisms, and Therapeutic Potential
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/frontiers-in-immunology-2-medicinal-plants-in-diabetic-nephropathy-bioactive-compounds-mechanisms-and
- **Specialty:** [Nephrology](https://medichelpline.com/clinical-feed/nephrology.md)
- **Primary Source:** Frontiers in Immunology
- **Source URL:** [Original Journal Publication](https://www.frontiersin.org/articles/10.3389/fimmu.2026.1964602)
- **Published At:** 2026-11-12T00:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Diabetic nephropathy (DN) arises from persistent hyperglycemia triggering oxidative stress, innate immune signaling, proinflammatory cytokines, AGEs, RAAS activation, and extracellular matrix deposition. - Standard therapies—glycemic control, antihypertensives, RAAS blockade, **SGLT2 inhibitors**, GLP‑1 receptor agonists, and finerenone—slow progression but leave residual risk of kidney and cardiovascular outcomes. - The review screened literature from 1990–2026 across seven databases and included 257 articles after initial identification of 514 records; inclusion required experimental or clinical data on antidiabetic or renoprotective effects of medicinal plants. - Multiple in vitro and in vivo studies reported nephroprotective effects mediated by antihyperglycemic, antioxidant, anti-inflammatory, antiapoptotic, and lipid‑lowering actions, plus inhibition of innate immune pathways. - Prominent phytoconstituents discussed include **quercetin**, rutin, **curcumin**, berberine, mangiferin, gallic acid, and thymoquinone; these showed improvements in renal biomarkers, reduced oxidative stress, and preserved renal histology in preclinical models. - The review noted mechanistic overlap between phytochemicals and contemporary DKD therapies through modulation of NLRP3, NF‑κB, and TGF‑β1/Smad signaling, but did not claim replacement of standard care. - Limitations highlighted by the authors include variability in phytochemical composition, standardization challenges, limited bioavailability data, uncertain dosing, potential drug–herb interactions, and a paucity of well‑designed clinical trials to support routine clinical use. - The authors called for rigorous clinical trials and further pharmacological characterization before medicinal plants can be integrated as adjunctive agents alongside evidence‑based DKD therapies.
## Clinical Analysis & Structured Key Points
Frontiers | Medicinal plants in diabetic nephropathy: bioactive compounds, mechanisms, and therapeutic potential REVIEW article Front. Immunol. , 12 November 2026 Sec. Molecular Innate Immunity Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1964602 Published in Frontiers in Immunology Molecular Innate Immunity 7 impact factor 11.3 citescore Part of a Research Topic Innate Immunity and Metabolic Disorders: Molecular Mechanisms and Therapeutic Implications 47k views 16 articles Editor & Reviewers Edited by S J Shang-Rong Ji Reviewed by J G Jing Guo P L Pongrapee Laorodphun S J Sahadeb Jana Outline Figures and Tables Figure 1 View in article Figure 2 View in article Figure 3 View in article Table 1 Medicinal plants and their pharmacological effectiveness against diabetes and DN. View in article Table 2 Medicinal plants and their phytoconstituents with promising effects against diabetes and DN. View in article Table 3 Clinical trial findings of alternative therapies against DN. View in article REVIEW article Front. Immunol. , 12 November 2026 Sec. Molecular Innate Immunity Volume 17 - 2026 | https://doi.org/10.3389/fimmu.2026.1964602 Medicinal plants in diabetic nephropathy: bioactive compounds, mechanisms, and therapeutic potential S A Samia Akther 1 F A Fahmida Alam 2 T R Tahmeed Rezwan Shushmoy 1 S A Sumaiya Akter Annie 1 M A Md. Abeduzzaman Anon 1 M S Md. Shah Amran 1 K U Kamran Ul Baset 3 M J Md. Josim Uddin 1 * 1. Department of Pharmacy, Independent University, Bangladesh, Dhaka, Bangladesh 2. Department of Life Sciences, Independent University, Bangladesh, Dhaka, Bangladesh 3. Department of Public Health, Independent University, Bangladesh, Dhaka, Bangladesh See more Article metrics View details Abstract Diabetic nephropathy (DN) is known as one of the most critical microvascular complications associated with diabetes mellitus, and is a primary cause of chronic kidney disease and end-stage renal disease worldwide. Renal injury in DN is primarily driven by persistent hyperglycemia, which sequentially triggers oxidative stress, activation of innate immune signaling pathways, pro-inflammatory cytokine production, accumulation of advanced glycation end products, activation of the renin–angiotensin–aldosterone system (RAAS), and extracellular matrix deposition. Exisitng treatments, such as glycemic control, antihypertensive agents, and RAAS inhibitors, are efficacious in slowing disease progression. Alongside these standard therapies, medicinal plants and their bioactive constituents have garnered substantial attention as potential complementary approaches. The aim of this review is to highlight the therapeutic potential of medicinal plants and their phytoconstituents, leading to the prevention and management of DN, while elucidating associated pharmacological mechanisms. Several in vitro and in vivo studies have shown that various medicinal plants exert nephroprotective effects through antihyperglycemic, antioxidant, anti-inflammatory, anti-apoptotic, and lipid-lowering mechanisms, as well as by inactivating innate immune pathways. Notable phytoconstituents, including quercetin, rutin, curcumin, berberine, mangiferin, gallic acid, and thymoquinone, have demonstrated promising potential in enhancing renal biomarkers, reducing oxidative stress, suppressing inflammatory mediators, and preserving renal tissue structure. Altogether, medicinal plants emerge as promising multi-target therapeutic candidates for DN, warranting rigorous clinical trials to better evaluate their future therapeutic translation. 1 Introduction Diabetes mellitus (DM) is characterized by chronic hyperglycemia resulting from impaired insulin secretion, insulin resistance, or a combination of both ( 1 ). Persistent hyperglycemia leads to a broad spectrum of complications due to progressive damage imposed on several organs and systems. Complications related to DM can be classified as microvascular and macrovascular. Microvascular complications, including diabetic retinopathy, neuropathy, and nephropathy, account for major contributions to morbidity in the diabetic population ( 1 ). In contrast, macrovascular complications, entailing coronary heart disease, peripheral vascular disease, and ischemic stroke, prevail as the leading cause of mortality among diabetic patients ( 2 ). Notably, as a primary microvascular complication, diabetic nephropathy (DN) prevails as a major driver of end-stage renal disease (ESRD) and a defining stage in the progression of renal microvascular damage ( 3 ). DM stands as the leading cause of ESRD at present times, which often requires treatments like dialysis or kidney transplantation. However, it is important to highlight that numerous individuals may succumb to cardiovascular diseases before reaching ESRD, stemming from the well-established link between DN and cardiovascular morbidity ( 2 ). The clinical presentation of DN is characterized by elevated arterial blood pressure, chronic albuminuria, and a progressive decline in glomerular filtration rate (GFR). Exacerbated hypertension and ongoing proteinuria aggravate these clinical features. Further acceleration of renal deterioration is driven by additional factors, including dysregulated glycemic control and abnormal lipid metabolism, though these risk factors warrant further characterization ( 4 ). The pathophysiology of DN remains complex and incompletely elucidated despite advances in medical science; this ambiguity limits the efficacy of clinical treatment, resulting in elevated healthcare costs and suboptimal clinical outcomes ( 5 ). The existing therapies focus primarily on managing metabolic and hemodynamic disturbances, including glycemic control and blood pressure regulation ( 6 ). However, the therapeutic landscape of diabetic kidney disease (DKD) has evolved considerably. Current management extends beyond conventional glycemic and blood pressure control. Renin–angiotensin–aldosterone system (RAAS) blockade remains a component of therapy, while sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as key kidney and cardiovascular-protective therapies for eligible patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) ( 7 ). Glucagon-like peptide-1 (GLP-1) receptor agonists have also gained a role because of their demonstrated cardiovascular benefits and emerging evidence of kidney-protective effects ( 8 ). In addition, the non-steroidal mineralocorticoid receptor antagonist finerenone has demonstrated kidney and cardiovascular benefits in patients with T2DM and CKD, representing another important disease-modifying option ( 7 , 9 ). Despite these advances, DKD continues to carry a substantial residual risk of kidney disease progression and cardiovascular complications, indicating that existing interventions do not eliminate all aspects of disease burden ( 10 ). Therefore, there remains a rationale for investigating approaches that may provide additional nephroprotective effects alongside established pharmacological therapies rather than replacing them. Such limitations mandate greater attention to alternative and complementary therapeutic strategies, particularly in therapeutic agents derived from natural sources and medicinal plants. Plant-derived bioactive compounds are gaining traction for their efficacy, safety, and accessibility in the treatment of DM and its complications ( 11 ). For example, phytoconstituents have been investigated for their ability to modulate pathways including NOD-like receptor family pyrin domain containing 3 (NLRP3), nuclear factor kappa B (NF-κB), and transforming growth factor beta-1 (TGF-β1)-associated signaling which are implicated in inflammation, oxidative stress and renal fibrosis ( 12 , 13 ). Importantly, several of these effects overlap with pathological pathways already influenced by contemporary DKD therapies. This mechanistic overlap does not imply that medicinal plants can replace therapies; rather, it provides a scientific basis for investigating whether plant-derived compounds may complement existing treatment strategies through additional or overlapping mechanisms. Recent reviews have proposed phytochemicals and medicinal plants as potential adjunctive approaches in DKD management while emphasizing the need for stronger clinical evidence before their routine incorporation into clinical practice ( 13 , 14 ). The affordability and availability of herbal remedies in many developing countries provide distinct advantages over conventional medicines. Nevertheless, the therapeutic translation of plants remains challenging due to variations in phytochemical composition, difficulties in standardization, limited bioavailability, uncertainty about optimal dosage, potential drug–herb interactions, and the limited number of adequately designed clinical trials ( 15 ). Medicinal plants and their phytoconstituents, therefore, offer an avenue for the complementary management of DKD, but their potential should be evaluated alongside, rather than in opposition to, established evidence-based therapies. The primary aim of this review is to investigate the potential of medicinal plants and their bioactive compounds in the prevention and management of DN. This article will also explore the mechanisms underlying their nephroprotective effects and discuss their potential future applications as complementary or adjunctive therapeutic agents in contemporary DKD management. 2 Literature search methods This review article was written by conducting literature searches covering the period between 1990 and 2026 across seven databases: Web of Science, PubMed, Google Scholar, ScienceDirect, Scopus, the Cochrane Library, and Google. The search employed keywords including diabetes mellitus, diabetic nephropathy, medicinal plants, traditional plants for kidney dysfunction, and alternative therapies. Following preliminary screening, an initial pool of 514 potentially relevant records was identified; and 257 articles were scrutinized and included to construct the primary focus of this review detailing the botanical therapies. Articles were included if they provided experimental ( in vitro or in vivo ) or clinical evidence on the antidiabetic or renoprotective effects of medicinal plants and isolated phytochemicals in DM and DN models. Studies were excluded if they met any of the following criteria: duplicate records, conference proceedings, book chapters, meta-analyses, case studies and case series, or studies failing to evaluate relevant renal biomarkers or metabolic parameters. 3 Epidemiology The incidence of DM is globally rising at an alarming rate ( 6 ). At present, DM affects ~537 million people worldwide, accounting for 10% of the overall population. This estimation is expected to rise to ~783 million by 2045 ( 1 ). Nearly 90% of all occurrences of DM are T2DM, which typically affects those who are ≥40 years old. Roughly 10% of diabetic people have type 1 diabetes mellitus (T1DM), commonly referred to as juvenile onset DM, which is brought on by the autoimmune destruction of the pancreatic beta cells ( 2 , 3 ). DKD is now the most common cause of ESRD worldwide. An increased incidence risk of ESRD is reported mostly in older patients aged between 45 and 64 years ( 4 ). Furthermore, individuals with T1DM have a higher risk of developing nephropathy compared to those with T2DM. However, due to the larger number of people with T2DM, there are more cases of nephropathy in this group overall ( 5 ). Although other factors can lead to kidney damage in individuals with DM, a diagnosis of DN is strongly indicated by specific key features. Renal biopsies are commonly used to identify the underlying cause of kidney disease, but are typically reserved for suspected non-diabetic conditions rather than for patients with diabetes ( 16 ). The presence of both albuminuria and retinopathy indicates an increased likelihood of DN, which is often associated with the development of Kimmelstiel-Wilson lesions, a form of nodular glomerulosclerosis ( 6 ). Clinical guidelines indicate that CKD can be linked to DM when either macroalbuminuria (>300 mg/24 hour) or microalbuminuria (30–300 mg/24 hour) is present, alongside diabetic retinopathy or a history of diabetes for more than 10 years ( 17 ). On the other hand, if retinopathy and autonomic neuropathy are absent at the time of diabetes diagnosis, it suggests a non-diabetic origin for persistent albuminuria in individuals with DM ( 18 ). 4 Etiology The progression of DN in T1DM and T2DM is linked to increased urine albumin excretion, initially presenting as microalbuminuria (30–300 mg/g creatinine in a spot urine sample) ( 17 ). Risk factors include a family history, uncontrolled blood glucose, duration of hyperglycemia, high blood pressure, alcohol consumption, smoking, poor diabetic diet knowledge, physical inactivity, obesity, and secondary diseases ( 11 ). Elevated glycated hemoglobin (HbA1c) levels decrease GFR, and effective glucose control reduces albuminuria risk ( 19 ). Diabetic patients are twice as likely to develop hypertension ( 20 ), and the coexistence of hypertension and diabetes for 10–15 years leads to nephropathy due to sodium retention and increased vascular resistance ( 21 ). Dyslipidemia accelerates DN via increased low-density lipoprotein (LDL), very low-density lipoprotein (VLDL), triglyceride (TG), and decreased high-density lipoprotein (HDL) ( 22 ), promoting glomerulosclerosis and nephropathy ( 18 ). A high body mass index is associated with the development of DN and the progression to ESRD due to increased GFR, elevated capillary hydrostatic pressure, and proteinuria, all of which contribute to the onset of ESRD ( 23 ). In addition, smoking promotes microalbuminuria, arterial stiffness, oxidative stress, and renal vasoconstriction in diabetic patients ( 17 , 24 ). Diabetic retinopathy is prevalent in patients with proteinuria or dialysis, reflecting systemic microvascular damage and declining renal function ( 25 ). Elevated oxidative stress markers and increased levels of proinflammatory cytokines contribute to the development of DN and accelerate the decline in renal function ( 26 ). Matrix metalloproteinases (MMPs) modulate extracellular matrix (ECM) dynamics in DN, and abnormal MMP activity disrupts ECM, promoting renal hypertrophy and fibrosis ( 27 ). 5 Pathophysiology CKD is characterized by a variety of hemodynamic, metabolic, cellular, and molecular abnormalities. In case of DN, the majority of these changes are predominantly caused by persistent hyperglycemia and may lead to other pathological abnormalities ( 28 ). A hallmark histological feature of DN is the increased accumulation of ECM in both the glomerulus and interstitium. This excessive buildup leads to glomerulosclerosis (scarring of the glomeruli) and arteriolosclerosis (thickening of arterioles), which result in reduced glomerular perfusion and a loss of blood flow auto-regulation. However, evidence also suggests that early hemodynamic changes precede glomerular fibrosis and play a role in the initial stages of DN development ( 29 ). DN is triggered by glomerular hyperfiltration, where high blood glucose triggers the release of vasoactive mediators, including prostaglandins, nitric oxide (NO), insulin-like growth factor-1 (IGF-1), glucagon, and vascular endothelial growth factor (VEGF). These mediators lead to the dilation of afferent arterioles. Alongside these vascular changes, early DM also involves alterations in renal tubular function, which are linked to the degree of glycemic control. The tubuloglomerular feedback mechanism reduces sodium chloride levels reaching the macula densa in the distal tubules, causing further dilation of afferent arterioles. Concurrently, elevated angiotensin II levels induce constriction of the efferent arterioles, resulting in disrupted auto-regulation and the development of glomerular hypertension ( 30 ). This excessive angiotensin II activity reflects an overactivation of the RAAS, a central driver of progressive renal damage. Given their role in disease progression, clinicians rely on angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) to block the RAAS, control blood pressure, and reduce proteinuria ( 31 ). Irreversible reactive advanced glycation end products (AGEs) form irreversibly due to the non-enzymatic glycation of proteins and lipids under hyperglycemic conditions. Their accumulation in kidney tissues is linked to harmful effects in the glomeruli, such as increased vascular permeability, higher production of cytokines and growth factors, and upregulation of matrix proteins ( 32 ). In DN, AGEs cause damage by triggering receptor-mediated cellular responses and altering extracellular protein structure and function. Unlike in non-diabetic renal diseases, the interaction between AGEs and their receptor (RAGE) leads to distinct pathological outcomes that are differentially regulated in DN ( 33 ). Glomerular endothelial cells, podocytes, and mesangial cells have shown an upregulation of RAGE expression in DN ( 34 ). Additionally, the AGE–RAGE interaction in podocytes is believed to play a major role in activating oxidative stress and innate immune responses, contributing to the progression of DN ( Figure 1 ) ( 35 ). Figure 1 Pathophysiology of DN. Oxidative stress plays a significant role in mediating the early stages of cellular damage seen in diabetes-related complications. Reactive oxygen species (ROS) are generated when elevated intracellular glucose levels are oxidized through the citric acid cycle. This occurs due to an increase in electron donors, such as NADH and FADH 2 , entering the electron transport chain, which disrupts normal ATP synthesis in the mitochondria ( 36 ). The addition of electrons to oxygen generates highly unstable ROS. These radicals oxidize proteins, lipids, carbohydrates, and DNA, causing structural damage and dysfunction to cells. Concurrently, ROS induce cellular dysfunction by promoting lipid peroxidation (LPO), activating NF-κB and protein kinase C (PKC), increasing peroxynitrite production, and triggering apoptosis ( 37 ). Furthermore, oxidative stress directly activates the TGF-β1, Smad, and mitogen-activated protein kinase (MAPK) signaling pathways. This activation suppresses MMP production, driving the abnormal accumulation of ECM proteins. Ultimately, this disrupted ECM regulation leads to mesangial matrix expansion, tubular fibrosis, and glomerulosclerosis ( Figure 1 ) ( 38 ). In DN, proteinuria activates the RAAS. Angiotensin II causes changes that lead to glomerular sclerosis by enhancing the production of chemotactic factors, adhesion molecules, and fibrogenic cytokines, while also disrupting the balance between extracellular matrix formation and degradation. Increased levels of angiotensin II have been reported in DN as a result of proteinuria and ROS ( 1 ). Podocytes accumulate damaged mitochondria and oxidized proteins due to angiotensin II, which stimulates the production of ROS. This process triggers autophagy in the cells and leads to an increase in glomerular filtration ( Figure 1 ) ( 35 ). Nephropathy was initially considered a non-immune disease. However, recent research indicates that immune responses and inflammation are key drivers of its onset and progression ( 1 ). Studies suggest that inflammatory cytokines contribute to microvascular complications, including DN, retinopathy, and neuropathy. Hyperglycemic conditions activate innate immune pathways that produce these cytokines and exacerbate inflammation ( 39 ). Elevated levels of pro-inflammatory cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-18 (IL-18), and tumor necrosis factor-alpha (TNF-α) in both local and invading glomerular cells are linked with DN ( Figure 1 ) ( 35 ). More specifically, in DN, innate immune activation mainly depends on pattern recognition re
## Related Clinical Research

- [Lifestyle Changes May Help Prevent Multimorbidity In Prediabetes](https://medichelpline.com/clinical-feed/medical-news-today-23-diet-weight-loss-and-150-minutes-of-exercise-may-protect-against-chronic.md)
- [Moving Forward: The Future of GLP-1 Therapies](https://medichelpline.com/clinical-feed/endocrine-news-18-moving-forward-the-future-of-glp-1-therapies.md)
- [Cardiometabolic multimorbidity among Ghanaian clinic patients: clinical, lifestyle and genetic cor](https://medichelpline.com/clinical-feed/plos-one-19-cardiometabolic-multimorbidity-and-associated-clinical-lifestyle-and-genetic.md)
- [Self-Management Program Lowers HbA1c, eGFR, SBP, LDL-C in High-Risk DKD Patients with Type 2 Diabe](https://medichelpline.com/clinical-feed/plos-one-11-effectiveness-of-a-self-management-intervention-on-clinical-outcomes-among.md)
- [SGLT2 Inhibitors and Rheumatoid Arthritis Risk in Type 2 Diabetes: Summary of Reported Emulated Ta](https://medichelpline.com/clinical-feed/frontiers-in-immunology-19-the-association-between-sglt2-inhibitors-and-rheumatoid-arthritis-risk-in-type.md)

## Navigation
- [← Back to Nephrology Feed](https://medichelpline.com/clinical-feed/nephrology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.